01:38 , Mar 1, 2019 |  BC Week In Review  |  Company News

Abpro, NJCTTQ to develop bispecific antibodies in immuno-oncology

Antibody company Abpro Corp. (Woburn, Mass.) has partnered with Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd. (NJCTTQ) to use Abpro’s DiversImmune antibody discovery platform to develop multiple bispecific antibodies, including T cell engagers, to treat...
15:12 , Feb 28, 2019 |  BC Extra  |  Company News

Abpro, NJCTTQ to develop bispecific antibodies in immuno-oncology

Antibody company Abpro Corp. (Woburn, Mass.) has partnered with Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd. (NJCTTQ) to use Abpro’s DiversImmune antibody discovery platform to develop multiple bispecific antibodies, including T cell engagers, to treat...
22:50 , Sep 28, 2018 |  BC Extra  |  Company News

Management tracks: Zai, Selecta

Zai Lab Ltd. (NASDAQ:ZLAB) hired Tao Fu as COO. Fu was EVP and chief commercial and business officer of Portola Pharmaceuticals Inc. (NASDAQ:PTLA) (see "Amid Launch Troubles, Portola Commercial Chief Fu Resigns" ). Prior to...
04:48 , May 17, 2018 |  BC Extra  |  Financial News

Abpro withdraws IPO

Antibody company Abpro Corp. (Woburn, Mass.) is withdrawing a planned IPO on NASDAQ, according to an SEC filing on May 16. Underwriters were to be UBS, Wells Fargo, Nomura and Oppenheimer. Earlier this month, Abpro...
02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...
17:21 , Apr 13, 2018 |  BC Week In Review  |  Financial News

Abpro planning $69M NASDAQ listing

Antibody company Abpro Corp. (Woburn, Mass.) filed on April 12 to raise up to $69 million in an IPO on NASDAQ underwritten by UBS, Wells Fargo, Nomura and Oppenheimer. Abpro's two lead programs, ABP-100 and...
17:20 , Apr 12, 2018 |  BC Extra  |  Financial News

Abpro planning $69M NASDAQ listing

Antibody company Abpro Corp. (Woburn, Mass.) filed to raise up to $69 million in an IPO on NASDAQ underwritten by UBS, Wells Fargo, Nomura and Oppenheimer. Abpro's two lead programs, ABP-100 and ABP-201, are designed...
21:49 , Dec 2, 2016 |  BC Week In Review  |  Company News

Abpro, AstraZeneca deal

The MedImmune LLC unit of AstraZeneca and Abpro partnered to develop MedImmune's preclinical bispecific antibody that targets angiopoietin 2 ( ANG2 ; ANGPT2) and VEGF for multiple undisclosed indications. Abpro will use its DiversImmune platform...
07:00 , May 30, 2016 |  BC Week In Review  |  Company News

Abpro, Brigham and Women’s Hospital deal

Abpro and the hospital partnered to discover and co-develop mAbs for fibrosis. The partners will use Abpro’s DiversImmune antibody discovery platform. Abpro will have commercialization rights to resulting antibodies. Abpro declined to disclose financial terms,...
07:00 , May 30, 2016 |  BC Week In Review  |  Company News

Abpro, Massachusetts General Hospital deal

Abpro and the hospital partnered to discover and co-develop mAbs in cancer, inflammation and autoimmunity. The partners will use Abpro’s DiversImmune antibody discovery platform. Abpro will have commercialization rights to resulting antibodies. Abpro declined to...